Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Stock (London, United Kingdom), A. De Lauretis (London, United Kingdom), D. Visca (London, United Kingdom), C. Daccord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), T. Maher (London, United Kingdom), V. Ong (London, United Kingdom), D. Abraham (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom). Serum biomarkers in SSc-ILD: association with presence, severity and prognosis. 5198

Member's Comments

No comment yet.

Related content which might interest you: Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 The relationship between the serum YKL-40 level and severity of asthma Source: Annual Congress 2012 - Asthma management Year: 2012 Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study. Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Gender differences in plasma biomarkers levels in patients with COPD Source: Annual Congress 2010 - Novel markers of lung injury Year: 2010 Plasma levels of circulating cell-free DNA are increased in idiopathic pulmonary fibrosis but do not correlate with disease severity Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Characterisation of asthma subgroups associated with circulating YKL-40 levels Source: Eur Respir J, 50 (4) 1700800; 10.1183/13993003.00800-2017 Year: 2017 The relationship between level of C-reactive protein in blood serum and clinical manifestations of the disease in patients with pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis: metabolic insights Year: 2010 Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019